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Background: Glioblastomas, the most common and malignant brain tumors of the central nervous system, exhibit
high invasive capacity, which hinders effective therapy. Therefore, intense efforts aimed at improved therapeutics
are ongoing to delineate the molecular mechanisms governing glioma cell migration and invasion.
Methods: In order to perform the studies, we employed optimal cell culture methods and hypoxic conditions,
lentivirus-mediated knockdown of protein expression, Western Blot analysis, migration assays and
immunoprecipitation. We determined statistical significance by unpaired t-test.
Results: In this report, we show that U87MG, LN229 and LN308 glioma cells express CXCR7 and that exposure to
hypoxia upregulates CXCR7 protein expression in these cell lines. CXCR7-expressing U87MG, LN229 and LN308
glioma cells migrated towards stromal-derived factor (SDF)-1α/CXCL12 in hypoxic conditions in the Boyden
chamber assays. While shRNA-mediated knockdown of CXCR7 expression did not affect the migration of any of the
three cell lines in normoxic conditions, we observed a reduction in the migration of LN229 and LN308, but not
U87MG, glioma cells towards SDF-1α in hypoxic conditions. In addition, knockdown of CXCR7 expression in LN229
and LN308 glioma cells decreased levels of SDF-1α-induced phosphorylation of ERK1/2 and Akt. Inhibiting CXCR4 in
LN229 and LN308 glioma cells that were knocked down for CXCR7 did not further reduce migration towards
SDF-1α in hypoxic conditions and did not affect the levels of phosphorylated ERK1/2 and Akt. Analysis of
immunoprecipitated CXCR4 from LN229 and LN308 glioma cells revealed co-precipitated CXCR7.
Conclusions: Taken together, our findings indicate that both CXCR4 and CXCR7 mediate glioma cell migration
towards SDF-1α in hypoxic conditions and support the development of therapeutic agents targeting these
receptors.
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CXCR4 is a well-known G-protein coupled receptor
(GPCR) for the small chemokine stromal-derived factor
(SDF)-1α, which is also known as CXCL12. Another
GPCR, CXCR7, has been identified as a second receptor
for SDF-1α. This receptor was originally cloned based
on its homology with conserved domains of GPCRs and
named as “RDC1” [1]. At the beginning, it was believed to
be a receptor for vasointestinal peptide, but later reports
dismissed this possibility [2]. Combined phylogenetic and* Correspondence: david.zagzag@nyumc.org
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reproduction in any medium, provided the orchromosomal location studies revealed the structural re-
semblance of the orphan receptor RDC1 to CXC chemo-
kine receptors and implicated CXC chemokines as
potential ligands [1]. It was shown that RDC1 could serve
as a co-receptor for human immunodeficiency virus and
simian immunodeficiency virus strains, just like CXCR4
[3]. Soon afterwards, SDF-1α was shown to bind with high
affinity to and signal through the orphan receptor RDC1
[2], leading to the designation of the receptor as “CXCR7”.
CXCR7 is expressed on vascular endothelial cells, T cells,
dendritic cells, B cells, brain-derived cells and tumor cells,
including human glioma cells [2-4]. Its expression is
upregulated by hypoxia in human microvascular endothe-
lial cells [5]. CXCR7 plays an important role in several car-
cinomas, including breast cancer, lung cancer, and prostatel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Hypoxia upregulates CXCR7 protein expression.
(a) U87MG, (b) LN229 and (c) LN308 glioma cells were cultured in
normoxic or hypoxic conditions for 3, 6, 12, 18 and 24 h. Total cell
lysates were collected and analyzed by Western blot for HIF-1α and
CXCR7 protein expression. β-Actin was used as loading control. Data
are representative of two independent experiments with similar
results. N, normoxia (20% O2); H, hypoxia (1% O2).
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melanoma sections demonstrated CXCR7 staining on
tumor cells [5]. This receptor is believed to play a pivotal
role in growth, adhesion, survival, angiogenesis, and inva-
sion of tumor cells [2,6,7]. Administration of a small mol-
ecule antagonist of CXCR7 correlated with reduced tumor
size in both xenograft and syngeneic in vivo tumor growth
studies [6]. Ectopic expression of the receptor has been
shown to enhance tumor formation in nude mice in vivo
[8]. A recent study demonstrated that in prostate cancer,
CXCR7 potentially promotes invasion through its down-
stream targets of CD44 and cadherin-11 [7]. Balabanian
and colleagues showed that SDF-1α-induced T cell migra-
tion was dependent on both CXCR4 and CXCR7, and
combined inhibition of these two receptors resulted in
additive inhibitory effects on the migration of T cells [2].
Hypoxia is a major player in the microenvironment of
gliomas that orchestrates adaptive responses by sti-
mulating the expression of several genes involved in tu-
morigenesis. However, despite accumulating data, the
regulation of CXCR7 by hypoxia and its contribution to
glioma migration have not been fully elucidated yet. Here,
we show that U87MG, LN229 and LN308 glioma cells
express CXCR7 and exposure to hypoxia upregulates
CXCR7 protein expression in these cell lines. CXCR7-
expressing U87MG, LN229 and LN308 glioma cells
migrated towards SDF-1α in hypoxic conditions in the
Boyden chamber assays. While shRNA-mediated knock-
down of CXCR7 expression did not affect the migration of
any of the three cell lines in normoxic conditions, we ob-
served a reduction in the migration of LN229 and LN308,
but not U87MG, glioma cells towards SDF-1α in hypoxic
conditions. In addition, knockdown of CXCR7 expression
in LN229 and LN308 glioma cells decreased levels of
SDF-1α-induced phosphorylation of ERK1/2 and Akt. In-
hibiting CXCR4 in LN229 and LN308 glioma cells that
were knocked down for CXCR7 did not further reduce
migration towards SDF-1α in hypoxic conditions and did
not affect the levels of phosphorylated ERK1/2 and Akt.
Analysis of immunoprecipitated CXCR4 from LN229 and
LN308 glioma cells revealed co-precipitated CXCR7.
Taken together, our findings indicate that both CXCR4
and CXCR7 mediate glioma cell migration towards SDF-
1α in hypoxic conditions.
Results
Hypoxia upregulates CXCR7 protein expression
We first determined the effect of hypoxia on CXCR7 pro-
tein expression in glioma cells. U87MG, LN229 and
LN308 glioma cells were cultured in normoxic or hypoxic
conditions for 3, 6, 12, 18 and 24 h. Total cell lysates were
collected and subjected to Western blot analysis (Figure 1).
We observed that U87MG, LN229 and LN308 glioma
cells expressed CXCR7. Exposure to hypoxia increasedHIF-1α and CXCR7 protein levels in all cell lines. In
LN229 (Figure 1b) and LN308 (Figure 1c) glioma cells,
hypoxia upregulated CXCR7 protein expression imme-
diately, starting at 3 h and declining after 18 h. Conversely,
in U87MG (Figure 1a) glioma cells, hypoxia upregulated
CXCR7 protein expression at 18 h, declining slowly there-
after. CXCR7 protein expression was upregulated signifi-
cantly by two-fold in U87MG and LN229, and three-fold in
LN308 glioma cells at 18 h.
Figure 2 CXCR7 mediates the migration of LN229 and LN308
glioma cells towards SDF-1α in hypoxic conditions.
shRNA-infected U87MG, LN229 and LN308 glioma cells were seeded
in migration chambers in the presence or absence of 100 ng/ml (10
nM) of SDF-1α in the lower well. They were allowed to migrate for 8
h in normoxic or hypoxic conditions. Bar graphs indicate the
average number of migrated cells per field. Error bars denote mean
± standard deviation. *P<0.001 versus normoxic control; **P<0.001
versus non-SDF-1α exposed cells; ***P<0.001 versus SDF-1α exposed
hypoxic cells. Bar graphs represent pooled data from two
independent experiments. N, normoxia (20% O2); H, hypoxia (1% O2);
white bars, shLacZ; grey bars, shCXCR7 S4; hatched bars,
shCXCR7 S5.
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glioma cells towards SDF-1α in hypoxic conditions
We have previously shown that CXCR4-positive glioma
cells increase their migration towards SDF-1α [9]. Both
CXCR4 and CXCR7 are receptors for SDF-1α. There-
fore, we wished to evaluate the role of CXCR7 in glioma
cell migration towards SDF-1α in normoxic and hypoxic
conditions. For this purpose, we first knocked down the
expression of CXCR7 in U87MG, LN229 and LN308 gli-
oma cells using a lentivirus-mediated shRNA vector di-
rected against the receptor. As control, cells were
infected with a lentivirus-mediated shRNA vector di-
rected against LacZ. The efficiency of knockdown was
confirmed by Western blot analysis (data not shown).
We selected two sequences that effectively knocked
down the expression of the receptor, S4 and S5, and
tested them both in the following migration experiments
to ensure consistent results.
To test whether CXCR7 knockdown reduces the number
of migrated cells towards SDF-1α, shRNA-infected U87
MG, LN229 and LN308 glioma cells were seeded in migra-
tion chambers in the presence or absence of 100 ng/ml of
SDF-1α in the lower well. They were allowed to migrate for
8 h in normoxic or hypoxic conditions. After fixing and
staining, the number of migrated cells was quantitated.
Results from two independent experiments are shown
(Figure 2). First, we observed that in hypoxic conditions, all
cell lines increased their migration significantly compared
to similar cultures in normoxic conditions (P< 0.001). Both
in normoxic and hypoxic conditions, and in the presence of
SDF-1α in the lower well, U87MG and LN308 glioma cells
showed a significant increase in migration towards SDF-1α
compared to control cultures (P< 0.001). By contrast,
LN229 glioma cells increased their migration towards SDF-
1α only in hypoxic conditions (P<0.001). In normoxic con-
ditions, knockdown of CXCR7 expression did not inhibit
the increased migration of glioma cells towards SDF-1α.
However, in hypoxic conditions, knockdown of CXCR7 ex-
pression significantly reduced the number of migrated
LN229 and LN308, but not U87MG, glioma cells towards
SDF-1α as compared to control cultures (P<0.001). This is
consistent with our observation that CXCR7 is not signifi-
cantly induced by hypoxia in U87MG cells during the 8 h
incubation period. Hypoxia upregulates CXCR7 in U87MG
glioma cells at 18 h (Figure 1).
Inhibiting CXCR4 in glioma cells that are knocked down
for CXCR7 does not further reduce migration
towards SDF-1α
We have previously shown that AMD3100, a CXCR4 in-
hibitor, decreases glioma cell migration towards SDF-1α
[9]. Since we observed that knockdown of CXCR7
expression similarly decreased migration towards SDF-
1α, we tested whether combined inhibition of these two
Figure 3 Inhibiting CXCR4 in glioma cells that are knocked
down for CXCR7 does not further reduce migration towards
SDF-1α. shRNA-infected LN229 and LN308 glioma cells were seeded
in migration chambers with or without 100 nM of AMD3100 and in
the presence or absence of 100 ng/ml (10 nM) of SDF-1α in the
lower well. They were allowed to migrate for 8 h in hypoxic
conditions (1% O2). Bar graphs indicate the average number of
migrated cells per field. Error bars denote mean ± standard
deviation. *P<0.001 versus non-SDF-1α exposed cells; **P<0.001
versus SDF-1α exposed cells. Bar graphs represent pooled data from
two independent experiments.
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migrated glioma cells towards SDF-1α. According to
previous results, knockdown of CXCR7 expression re-
duced the migration of only LN229 and LN308 glioma
cells towards SDF-1α at 8 h of incubation period, and
only in hypoxic conditions. Therefore, we carried out the
rest of migration studies according to these results.
shRNA-infected LN229 and LN308 glioma cells were
seeded in migration chambers with or without 100 nM of
AMD3100 and in the presence or absence of 100 ng/ml
of SDF-1α in the lower well. They were allowed to
migrate for 8 h in hypoxic conditions. After fixing and
staining, the number of migrated cells was quantitated.
Results from two independent experiments are shown
(Figure 3). Consistent with our earlier observations, mi-
gration of both LN229 and LN308 glioma cells increased
significantly towards SDF-1α as compared to control cul-
tures (P<0.001). Both AMD3100 and knockdown of
CXCR7 expression significantly inhibited the increased
migration of glioma cells towards SDF-1α (P<0.001).
However, inhibiting CXCR4 in LN229 and LN308 glioma
cells that were knocked down for CXCR7 expression did
not further reduce migration towards SDF-1α.
SDF-1α induces CXCR7-mediated phosphorylation of
ERK1/2 and Akt in LN229 and LN308 glioma cells
As we mentioned above, phosphorylated ERK1/2, Akt
and FAK play critical roles in glioma cell migration and
invasion. We previously provided evidence that SDF-1α
induces phosphorylation of ERK1/2, Akt and FAK in
LN308 glioma cells that display CXCR4-mediated mi-
gration towards SDF-1α [9]. As a first step to elucidate
molecular signaling pathways mediated by CXCR7, we
tested whether SDF-1α induces phosphorylation of
ERK1/2, Akt and FAK in LN229 and LN308 glioma cells
that demonstrate CXCR7-mediated migration towards
SDF-1α. LN229 and LN308 glioma cells infected with
shRNA vector directed against CXCR7 or LacZ were ex-
posed to SDF-1α for 15 min and analyzed for total and
phosphorylated ERK1/2, Akt and FAK by Western blot
analysis (Figure 4). We observed that SDF-1α increased
the levels of phosphorylated ERK1/2, Akt and FAK two-
fold, three-fold, and two-fold in LN229 and two-fold,
two-fold, and three-fold in LN308 glioma cells, respect-
ively. Knockdown of CXCR7 expression decreased the
levels of SDF-1α-induced phosphorylation of ERK1/2 and
Akt, but not FAK, two-fold in both glioma cell lines.
Inhibiting CXCR4 in glioma cells that are knocked
down for CXCR7 does not further reduce levels of
SDF-1α-induced phosphorylation of ERK1/2 and Akt
Exposure of glioma cells to SDF-1α in the presence of
AMD3100 decreases levels of phosphorylated ERK1/2 and
Akt [9]. We thus tested whether combined inhibition ofCXCR4 and CXCR7 results in further reduction in the
levels of phosphorylated ERK1/2 and Akt. LN229 and
LN308 glioma cells infected with shRNA vector directed
against CXCR7 or LacZ were exposed to SDF-1α for 15
min in the presence or absence of 100 nM of AMD3100
and analyzed for total and phosphorylated ERK1/2 and
Akt by Western blot analysis (Figure 5). Consistent with
our previous observations (Figure 4), knockdown of
CXCR7 expression decreased the levels of SDF-1α-induced
phosphorylation of ERK1/2 and Akt two-fold in both gli-
oma cell lines. However, inhibiting CXCR4 in LN229 and
Figure 4 SDF-1α induces CXCR7-mediated phosphorylation of ERK1/2 and Akt in LN229 and LN308 glioma cells. shRNA-infected LN229
and LN308 glioma cells were exposed to SDF-1α for 15 min and analyzed for total and phosphorylated ERK1/2, Akt and FAK by Western blot
analysis. Data represent one of two independent experiments.
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expression did not further reduce levels of SDF-1α-induced
phosphorylation of ERK1/2 and Akt.
CXCR4 and CXCR7 bind in glioma cells
Since our observations so far suggested a functional inter-
action between CXCR4 and CXCR7, we investigated the
potential binding of the two receptors in glioma cells. We
transfected LN229 and LN308 glioma cells with HA-
tagged CXCR4 (CXCR4-HA) or an empty vector as con-
trol. We then immunoprecipitated CXCR4-HA or empty
vector from LN229 and LN308 glioma cells and analyzed
it for co-precipitated CXCR7 using Western blotting
(Figure 6). Immunoprecipitation of CXCR4-HA led to theFigure 5 Inhibiting CXCR4 in glioma cells that are knocked down for
phosphorylation of ERK1/2 and Akt. shRNA-infected LN229 and LN308 g
absence of 100 nM of AMD3100 and analyzed for total and phosphorylated
independent experiments.detection of co-precipitated CXCR7. By contrast, CXCR7
was not detectable in the empty vector.
Discussion
Our findings demonstrate that (1) hypoxia upregulates
CXCR7 protein expression in glioma cells, (2) CXCR7 me-
diates the migration of LN229 and LN308 glioma cells to-
wards SDF-1α in hypoxic conditions, (3) SDF-1α induces
CXCR7-mediated phosphorylation of ERK1/2 and Akt in
LN229 and LN308 glioma cells, (4) inhibiting CXCR4 in
glioma cells that are knocked down for CXCR7 does not
further reduce either the migration towards SDF-1α or the
levels of SDF-1α-induced phosphorylation of ERK1/2 and
Akt, and (5) CXCR4 and CXCR7 bind in glioma cells.CXCR7 does not further reduce levels of SDF-1α-induced
lioma cells were exposed to SDF-1α for 15 min in the presence or
ERK1/2 and Akt by Western blot analysis. Data represent one of two
Figure 6 CXCR4 and CXCR7 bind in glioma cells. LN229 and
LN308 glioma cells were transfected with an empty vector
(EV) or HA-tagged CXCR4. Whole cell extracts (WCE) were
immunoprecipitated (IP) with anti-HA resin and samples were
subjected to Western blot analysis using anti-HA and anti-
CXCR7 antibodies. Data are representative of two independent
experiments with similar results.
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CXCR7 mediate glioma cell migration towards SDF-1α in
hypoxic conditions.
The presence of HIF-1α binding sites beginning
at −155, -1012 and −1350 base pairs upstream of the
transcription initiation site of CXCR7 suggests that its
expression could be regulated by hypoxia. Indeed, hyp-
oxia-induced upregulation of CXCR7 has been reported
previously in microvascular endothelial cells [5]. Our
data show that the expression of CXCR7 is upregulated
under hypoxic conditions in glioma cell lines. While
the upregulation is evident at earlier time points of ex-
posure to hypoxia in LN229 and LN308 glioma cells, it
is not noticeable until 18 h in U87MG glioma cells.
Hypoxia-mediated upregulation of CXCR7 is signifi-
cant, because hypoxia is a common pathological feature
of gliomas that controls the expression of many genes
essential for acquisition of invasive phenotype. The in-
vasive nature of gliomas hinders effective therapy and
thus molecular mechanisms governing invasion repre-
sent attractive therapeutic targets [9]. Although many
hypoxia-induced molecules that are involved in glioma
biology have been elucidated, more effective design of
treatment strategies warrants further identification of
novel hypoxia-responsive genes that drive invasion.
Although the key role of CXCR4 in mediating SDF-
1α-induced migration of glioma cells is well established
[9-12], that of CXCR7, to our knowledge, has still not
been confirmed. However, the discovery of CXCR7 as a
second SDF-1α receptor brings to mind the possibility
that CXCR7 might contribute to SDF-1α-induced migra-
tion. In a report by Balabanian et al., CXCR7 was de-
scribed as a receptor that enhanced SDF-1α-dependent
chemotaxis of T lymphocytes together with CXCR4 [2].
Our data support a role for CXCR7 in mediating SDF-
1α-induced glioma cell migration in hypoxic conditions.
Knockdown of CXCR7 expression by two independentshRNA sequences resulted in a consistent reduction in
the number of LN229 and LN308, but not U87MG, gli-
oma cells that migrated towards SDF-1α. The discrep-
ancy observed for the U87MG cell line is attributable to
the lack of hypoxia-mediated CXCR7 upregulation at 8
h of exposure to hypoxia (which is also the timeframe
for the migration assays). It should also be noted that
LN229 glioma cells migrated towards SDF-1α only in
hypoxic conditions, where levels of CXCR4 and CXCR7
were higher.
CXCR4 activation has been linked to ERK1/2, Akt,
and FAK phosphorylation [9], which are important path-
ways regulating the survival, proliferation and invasion
of tumor cells. Our data demonstrate that SDF-1α
induced the phosphorylation of ERK1/2 and Akt in LN229
and LN308 glioma cells that displayed CXCR7-mediated
migration towards SDF-1α. This was mediated by CXCR7,
as knockdown of CXCR7 expression decreased the levels
of SDF-1α-induced phosphorylation of ERK1/2 and Akt.
These data have important implications, because ERK1/
2 and Akt pathways are frequently upregulated in sev-
eral cancers and there are ongoing efforts exploring
both pathways as potential therapeutic targets. For in-
stance, positive staining for phosphorylated ERK1/2 is
observed in a large percentage of gliomas, but not in
normal brain. Indeed, inhibition of MAPK signaling by
the inhibitor sorafenib suppressed development of ma-
lignant glioma in an orthotopic mouse model [13].
Functionality of CXCR7 has long been the source of
controversy. To date, several studies have yielded puzzling
results. While some reports suggest a decoy activity,
others indicate a signaling activity for CXCR7. Burns and
colleagues showed that ligand activation of CXCR7 failed
to induce typical chemokine responses, such as cell migra-
tion and calcium mobilization [8]. This was supported by
studies in zebrafish that showed CXCR7 functions primar-
ily by sequestering SDF-1α to shape the extracellular che-
mokine gradient and provide directional migration [14].
By contrast, Wang and coworkers provided evidence that
CXCR7 induces invasiveness of prostate cancer cells and
activates Akt [7]. Invasiveness of hepatocellular carcinoma
cells is also mediated by CXCR7 [15]. There is evidence
that ligand binding to CXCR7 activates MAPK through β-
arrestin and thus the receptor is functional [16]. CXCR7 is
implicated in survival and proliferation of breast and lung
cancer cells [6]. Moreover, studies have unraveled that
CXCR7 regulates interneuron migration [17], and is in-
volved in transendothelial migration [18]. A recent study
reported that CXCR7 modulates chemokine responsive-
ness in migrating neurons by regulating CXCR4 protein
levels [19]. CXCR7 is also a functional receptor in primary
rodent astrocytes and controls proliferation and migration
towards SDF-1α through Gi/o proteins [20]. CXCR7 is in-
volved in mediating anti-apoptotic events in glioma cells
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CXCR4 and CXCR7. In GBM cell lines, CXCR7 controls
proliferation through a functional cross-talk with CXCR4
[23], and in the developing rat brain, a cross-talk between
CXCR4 and CXCR7 might account for the regulation of
SDF-1α-dependent neuronal development [24]. In breast
cancer cells, inhibition of CXCR7 was shown to reduce
the growth and metastasis of CXCR4-positive cells [25].
Targeting of CXCR7 also inhibits SDF-1α/CXCR4-medi-
ated transendothelial migration of human tumor cells [26].
We now provide evidence that CXCR7 is induced by
hypoxia, and mediates the migration of glioma cells to-
wards SDF-1α in hypoxic conditions. Our data reveal
that both CXCR4 and CXCR7 are required for migration
towards SDF-1α and SDF-1α-induced phosphorylation
of ERK1/2 and Akt. In LN229 and LN308 glioma cells,
both inhibition of CXCR4 by AMD3100 and shRNA-
mediated knockdown of CXCR7 expression diminished
migration towards SDF-1α and reduced levels of SDF-
1α-induced phosphorylation of ERK1/2 and Akt.
It is interesting that while both CXCR4 and CXCR7
are required for SDF-1α-induced migration of hypoxic
glioma cells, blocking both CXCR4 and CXCR7 does not
provide an additive effect, either with regards to migra-
tion assays or phosphorylation of ERK1/2 and Akt. Fur-
thermore, CXCR7 can be co-immunoprecipitated with
CXCR4-HA. It is probable that CXCR7 is part of a func-
tional heterodimer, together with CXCR4, which medi-
ates the migration of glioma cells towards SDF-1α under
hypoxic conditions. Functional CXCR4/CXCR7 hetero-
dimerization has previously been reported in HEK293T
cells and glial cells [27-29].
GPCRs can exist as monomers, homodimers or hetero-
dimers and these conformations might have important
implications in downstream signaling and the design of
pharmacological inhibitors. It has been demonstrated that
heterodimers can activate signaling pathways that differ
from those activated by homodimers [30]. Our previous
data showed that CXCR4 inhibition by AMD3100 de-
creased the levels of SDF-1α-induced phosphorylation of
FAK in LN308 glioma cells [9]. Conversely, the data that
we present here show that knockdown of CXCR7 expres-
sion in LN308 glioma cells did not affect the levels of
SDF-1α-induced phosphorylation of FAK. Activation of
FAK following exposure to SDF-1α might therefore de-
pend on CXCR4 alone. This scenario has obvious implica-
tions for drug discovery. Heterodimers may be considered
as distinct structural and functional entities, which might
influence drug affinity and efficacy. A better understand-
ing of how heterodimers are regulated, their function, and
pathophysiological significance may help us exploit them
as novel drug targets for improved therapeutics.
It is of note that, as mentioned above, CXCR4 and
CXCR7 are present on both tumor cells and vascularcells. This suggests that paracrine signaling mechanisms
between these two cell types might be in effect. Such
mechanisms could affect several aspects of tumor biol-
ogy, including angiogenesis, migration, survival and
proliferation.
Conclusions
In summary, the studies described here show that CXCR7
is a hypoxia-responsive mediator of SDF-1α-induced gli-
oma cell migration and support the development of thera-
peutic agents for the pharmacological inhibition of
CXCR4 and CXCR7 to control glioma cell migration.
Methods
Cell culture and reagents
Human glioma cell lines U87MG, LN229 and LN308
were obtained from ATCC. The human embryonic kid-
ney 293T (HEK293T) cells, used for lentivirus produc-
tion studies were kindly provided by Dr. Pagano, New
York University. Cell lines were cultured in 5% CO2 at
37°C in Dulbecco’s Modified Eagle Medium (DMEM,
Cellgro). The medium was supplemented with 10% fetal
bovine serum (FBS, Atlanta Biologicals), 1% penicillin
and streptomycin, and 2 mM glutamine (Gibco BRL).
For hypoxic exposure, cells were placed in a sealed
Modular Incubator Chamber (Billups-Rothenberg Inc.)
flushed with 1% O2, 5% CO2, and 94% N2. Recombinant
human SDF-1α/CXCL12 (R&D Systems Inc.) was pre-
pared in 0.1% BSA in PBS and stock solution (100 μg/
ml) was stored at −20°C. AMD3100, a CXCR4 inhibitor
[9] (Sigma-Aldrich), was prepared in PBS (5 mg/ml) and
kept at 4°C until used.
Western blot analysis
Cells were lysed in RIPA buffer supplemented with pro-
tease inhibitors [10]. Protein quantitation and electro-
phoresis were performed as previously described [10].
Western blot analysis was performed with the following
antibodies: rabbit anti-CXCR4 polyclonal antibody 1:500
(43 kDa; Imgenex), rabbit anti-CXCR7 polyclonal anti-
body 1:1000 (52 kDa; Abcam), rabbit anti-HIF-1α poly-
clonal antibody 1:500 (120 kDa; Bethyl Laboratories,
Inc.), mouse anti-p-ERK1/2 monoclonal antibody 1:1000
(44/42 kDa; Santa Cruz Biotechnology, Inc.), rabbit anti-
ERK1/2 polyclonal antibody 1:1000 (44/42 kDa; Cell Sig-
naling Technology, Inc.), rabbit anti-p-Akt polyclonal
antibody 1:1000 (60 kDa; Cell Signaling Technology,
Inc.), rabbit anti-Akt polyclonal antibody 1:1000 (60
kDa; Cell Signaling Technology, Inc.), rabbit anti-p-FAK
polyclonal antibody 1:1000 (125 kDa; Abcam), rabbit
anti-FAK polyclonal antibody 1:1000 (125 kDa; Abcam) and
mouse anti-actin monoclonal antibody 1:20,000 (42 kDa;
clone C4, Chemicon International, Inc.). Donkey anti-rabbit
and anti-mouse IgG horseradish peroxidase-conjugated
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were used at 1:2500 dilution. Immunodetection was car-
ried out with the Supersignal West Pico Chemilumines-
cent Reagent (Thermo Fisher Scientific). Visualization and
densitometry of protein bands were performed with the
National Institutes of Health (NIH) Image software (ver-
sion 1.62). In Figure 1, measurements of CXCR7 levels
were normalized to loading control, and in Figures 4 and
5, measurements of p-ERK 1/2, p-AKT and p-FAK were
normalized to total ERK 1/2, AKT, and FAK, respectively.
Migration assay
BD Biocoat chambers (BD Bioscience Discovery Labware)
with 8-μm pore size polycarbonate filter inserts for 24-
well plates were used according to the manufacturer’s in-
structions and as described [10]. Briefly, shRNA-infected
cells (1 × 10 [5]) were seeded onto the upper chambers in
400 μl of DMEM medium with 1% FBS in the presence or
absence of 100 nM of AMD3100 and placed into wells
containing 600 μl of complete medium with or without
SDF-1α (100 ng/ml) to induce cell migration. The migra-
tion chambers were incubated for 8 h in normoxic or hyp-
oxic conditions at 37°C. After incubation, the inserts were
fixed and stained and the number of migrating cells was
counted as described [10]. Each assay was performed in
duplicate and repeated two times with similar results. The
data from independent experiments were pooled for stat-
istical analysis.
Lentivirus production and infection of glioma cells
Five different shRNA sequences directed against CXCR7
were purchased from Open Biosystems and used to
knockdown CXCR7 expression in U87MG, LN229 and
LN308 glioma cells. Recombinant lentiviruses were pro-
duced by cotransfecting HEK293T cells with the lenti-
virus expression vector (pLKO.1 puro) and packaging
plasmids (Δ8.9 and vsv-g) using Fugene 6 (Roche Diag-
nostics) as a transfection reagent. Infectious lentiviruses
were collected at 24, 48 and 72 h after transfection and
the pooled supernatants centrifuged to remove cell deb-
ris and filtered through a 0.45 μm filtration unit. Glioma
cells were infected and stable transfectants were selected
in puromycin for 7 days. After this time, cells were ex-
panded and exposed to normoxic or hypoxic conditions to
test for CXCR7 downregulation. Two of the five shRNA
sequences (S4 and S5) efficiently downregulated CXCR7
expression in glioma cells based on Western blot analysis
and were used for further investigations.
Immunoprecipitation
For immunoprecipitation, 60%-80% confluent LN229 and
LN308 glioma cells were transfected with 5 ug of HA-
tagged CXCR4 (kindly provided by Dr. Marchese, Loyola
University Chicago) or empty vector as control usingX-tremeGENE HP DNA Transfection Reagent (Roche)
according to the manufacturer’s protocol. After 24 h, cells
were lysed in ice-cold NP-40 buffer [50 mM Tris- HCl pH
7.5 containing 0.5% Igepal CA-630, 150 mM NaCl, 10%
glycerol, 1 mM EDTA, 5 mM MgCl2 and protease inhibi-
tor cocktail (Sigma)]. After preclearing, lysates were incu-
bated with anti-HA antibodies (Covance) at 4°C for 1
hour, followed by another 1 hour incubation period in the
additional presence of protein G Sepharose beads (4B,
Invitrogen). The beads were washed three times in lysis
buffer and then resuspended in sample buffer. Samples
were later subjected to Western blot analysis using anti-
HA and anti-CXCR7 (Abcam) antibodies.
Statistical methodologies
Statistical significance was determined by unpaired t-test
(GraphPad Prism Software).
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